African American men are twice as likely to have more aggressive disease compared to non-African American men Read More

Deerfield commits up to $130 million over 10 years to accelerate Moffitt’s innovative drug discovery research Read More

Phase 2 study results show an exceptional response to nivolumab and ipilimumab combo therapy, no additional benefit when adding stereotactic body radiation therapy Read More

Subclone size is due to persistence with larger subclones arising early in life Read More

Stage 3A melanoma patients with larger sentinel node micrometastases have poorer outcomes and may benefit from adjuvant therapy Read More

Understanding the competing tumor suppressing and promoting effects of these fibroblasts could lead to more effective therapies Read More

The size of tumor and immune cell populations and their interactions over time impact outcomes to treatment Read More

Mistic open-source software allows multiplexed image t-SNE viewing Read More

Gains in chromosome 1q stimulate a network of competitive endogenous RNA molecules that promote melanoma metastasis Read More

Signaling through the protein YAP1 controls angiogenesis under normal and low oxygen conditions Read More

Survival risk tool based on expression of splice variants identifies patients at high risk of poor outcomes Read More

Strategic alliance significantly expands ongoing multi-year collaboration by granting Turnstone broader access and enhanced benefits at Moffitt Read More

Using evolutionary principles and mathematical modeling to outline an intermittent therapy approach using abiraterone can save patients as much as $70,000 Read More

The discovery reveals how the protein binds to ligands and inhibitory antibodies, and will improve cancer drug discovery Read More

Consecutive molecular modifications of the androgen receptor can contribute to drug resistance, which can be blocked with an ACK1 inhibitor Read More

These patterns predict the composition of the tumor immune environment and patient outcomes Read More

The alterations are associated with poor outcomes and disease progression Read More

Spatial organization and competition between drug-resistant cells affect treatment outcomes Read More

Chimeric antigen receptor T cells that target OR2H1 inhibit lung and ovarian tumor growth in mice Read More

The model uses radiomic features from screening images to inform lesions associated with very poor survival Read More

Tissue-resident memory T cells are important mediators of immune response Read More

The team used mathematical modeling to characterize the interplay between immune suppression, immune blockade and antigenicity Read More

Their company, Cadw Therapeutics, is partnering with SpacePharma to study stress and DNA damage caused by space travel in hopes of developing therapies to prevent it Read More

The new Florida budget awaiting the governor’s signature includes nearly $150 million allocated for the cancer center Read More

Moffitt study shows COVID prevalence between October 2020 and March 2021 was twofold higher Read More

Differences identified between acral and non-acral melanoma may lead to potential therapeutic targets Read More

The rate of developing antibodies varies by cancer type and treatment Read More

The discoveries from this multiomics study could drive new therapies for this rare cancer Read More

ΔNp63 controls enhancer regions of genes involved in the regulation of cell identity Read More

“Equal access system” shows how African American men are disproportionately affected Read More

IgA interactions with pIgR govern anti-tumor activity and are associated with improved outcomes Read More

Flores will oversee the Basic Science Division, which includes the Cancer Physiology, Drug Discovery, Immunology, Molecular Oncology and Tumor Biology departments Read More

Finding could potentially enhance response to immunotherapy for tumors that can’t be removed Read More

Using axicabtagene ciloleucel as a second-line treatment provided better outcomes compared to standard of care in phase 3 ZUMA-7 clinical trial Read More

Study shows it delays tumor growth and prolongs survival in mouse models Read More

New study finds dynamics between immune effector and suppressor cells can help show how radiation will impact a tumor Read More

Ana Gomes, Ph.D., will use the grant to study how aging impacts cancer Read More

The cancer center was awarded the NCI’s highest designation, Comprehensive Cancer Center, in recognition of its scientific and clinical impact and research excellence Read More

The cancer center is one of 75 sites selected for the study Read More

Researchers compared self-reported outcomes of patients treated with and without immunotherapy Read More

Health care initiative aims to provide free screening to adults with higher risks for multiple myeloma Read More

Model uses radiomic feature associated with low oxygen in tissues combined with clinical parameters Read More

Moffitt-initiated pilot study finds patients with checkpoint inhibitor resistant tumors are responding to tumor infiltrating lymphocyte treatment Read More

Study finds this HPV type and UV exposure increase skin cancer risk Read More

Amivantamab, an EGFR-MET biospecific antibody, has already received Breakthrough Therapy Designation by the FDA Read More

PARP16 is a novel functionally relevant target for talazoparib that enhances anti-cancer effects when drug is used alone or in combination with adavosertib Read More

Zeynep Eroglu, M.D., will receive funding to support clinical and research efforts Read More

Four distinct research projects will investigate common metabolic pathways that can be targeted therapeutically Read More

Researchers say results could help expand the public health potential of e-cigarettes Read More

New data shows computer models based on deep learning of PET/CT images can measure PD-L1 expression Read More

Findings may help better direct targeted treatments by identifying patient response in advance of therapy Read More

American Society of Clinical Oncology virtual conference is June 4-8 Read More

The COVID-19 pandemic has interrupted delivery of key health services for children and adolescents, including HPV vaccination for cancer prevention. Read More

BRAF V600E mutations are common in acral nevi Read More

Preclinical study finds TIM-3 suppresses DNA uptake and STING signaling Read More

Findings lead to the development of therapeutic strategies to overcome it Read More

Spatial constraints from the surrounding environment govern the evolution of tumors Read More

Competition with normal T cells and random extinction events influence patient outcomes Read More

Immunotherapy followed by BRAF and MEK inhibitors promotes anti-tumor immunity and suppresses signaling that leads to drug resistance Read More

Moffitt researchers find epithelial and mesenchymal subtypes of lung cancer cells respond differently to KRASG12C inhibitor therapy Read More

Cell turnover and cost of resistance are important factors that impact adaptive therapy Read More

Feb. 11 virtual event will highlight scientific advancements of health disparities research funded through the George Edgecomb Society Read More

IgA regulates immune cell activity by inhibiting RAS signaling and recognizing tumor markers Read More

Trial results show eprenetapopt plus azacitidine improves response Read More

This allows them to adapt to new environments more quickly Read More

Activation of certain transcription factors allow cells to select for a Warburg phenotype Read More

Cysteine starvation results in GCLC-induced peptide accumulation Read More

Researchers say people who have glioma are more likely to have antibodies to T. gondii Read More

Moffitt Cancer Center study suggests elevation in inflammation marker IL-6 linked to higher levels of fatigue Read More

Drug that blocks methylation restores SATB1 expression and may be effective against disease Read More

Together, immune content and Decipher scores can help determine which patients could benefit from targeted therapies Read More

The Patient Researcher Forum allows patients and researchers to learn from one another Read More

The 2020 Fellow class will be inducted in June Read More

The PET/CT-based deep learning model classifies EGFR mutation status in non-small cell lung cancer, identifying which treatment option is best Read More

TAp63 regulates long noncoding RNA molecules that promote tumor development by activating AKT Read More

The COLORS Training Program provides knowledge about LGBTQ+-related issues to help doctors better understand their patients’ needs Read More

The discovery could lead to development of new treatment strategies to help patients with advanced melanoma Read More

Low pH in lymph nodes inhibits effector T cells, while still allowing T cell activation Read More

New facility at AdventHealth Celebration offers cancer patients access to cutting-edge treatment and clinical trials Read More

Dorina Avram, Ph.D., brings strong immunology background and leadership to the new role Read More

Dr. Issam El Naqa will lead efforts to develop and apply machine learning techniques across the spectrum of cancer research Read More

Cytokines levels and the tumor microenvironment pre-treatment could play a key role Read More

The novel radiomics model can help identify which early stage lung cancer patients may need aggressive follow-up and/or adjuvant therapy Read More

Susan Vadaparampil, Ph.D., M.P.H., appointed to role by President Donald Trump Read More

The largest report of commercial CAR T therapy for lymphoma demonstrates its effectiveness even in patients that would not have been eligible for clinical trials Read More

Drs. Eric Haura and Nikhil Khushalani will guide the cancer center’s clinical science, clinical trials and expansion Read More

John Cleveland, Ph.D., has been named center director and executive vice president of Moffitt Cancer Center, one of 51 National Cancer Institute-designated comprehensive cancer centers in the country and the only one based in Florida. Read More

PERK protein controls myeloid-derived suppressor cells immunosuppression and may be an effective therapeutic target Read More

The model, based on changing levels of the biomarker PSA, can forecast patient responses to intermittent androgen deprivation therapy Read More

Delivery of certain microRNAs or targeting AURKA may be effective approaches for treatment Read More

Inhibition of HDAC11 blocks cancer stem cell self-renewal and overcomes drug resistance Read More

Moffitt Cancer Center partners with Haneke Design to develop AR-based app for innovative smoking cessation study Read More

Kowalczyk brings more than 30 years of clinical research operations and management experience to Moffitt Read More

The microenvironment of leptomeningeal melanoma metastases is enriched for molecules critical to melanoma cell survival and growth Read More

Leveraging tumor cell variability through adaptive treatment strategies maintains drug sensitivity Read More

New study suggests women who experience multiple PTSD symptoms have a much greater risk of developing the disease years later Read More

Moffitt Cancer Center study finds combination treatment of pembrolizumab and vorinostat is well tolerated, showing preliminary efficacy of therapy Read More

The genomically-adjusted radiation dose (GARD) can predict risk of local tumor recurrence and optimize radiation dose Read More

Two distinct populations of Merkel cell carcinoma identified; both exhibit similar responses to immunotherapy Read More

Combination therapy targeting KRAS mutation could provide benefit to nearly a third of lung cancer patients Read More

The subtypes have different genetic, chromosomal and protein alterations that could present therapeutic opportunities Read More

New study investigates disparity in cancer-related mortality among patients 65 or older with and without HIV Read More

Studies to expand its use in other cancers are ongoing at Moffitt Cancer Center Read More

The subtypes have different genetic, chromosomal and protein alterations that could present therapeutic opportunities Read More

Loss of the BCL-2 amplicon and transcriptional reprogramming contribute to resistance to the drug Venetoclax® for those with B-cell lymphomas Read More

Smokers who also vape e-cigarettes can help with research effort Read More

ABC News Political Commentator Cokie Roberts to host interview-style keynote address with Dr. Reid Huber Read More

Signaling properties and activity of CAR T cells are conditioned by the length of the CAR intracellular domain Read More

She leads a computational lab that models the mechanisms of interaction between tumors and their microenvironments Read More

Disparities experienced by LGBTQ patients, especially in cancer care, can lead to poorer outcomes and overall health. Read More

Read More

Suppression of GSK3 inhibits growth of KRas-driven tumors from pancreatic cancer patients who relapsed after chemotherapy or radiation. Read More

Read More

Phillip A. Sharp, Ph.D., will give lecture on his Nobel Prize winning cancer research Read More

New JAMA Oncology study shows daily use can reduce risk by 23 percent Read More

New study suggests midlife PSA testing is key to predicting aggressive prostate cancer Read More

Combining functional proteomics with deep network analysis leads to discovery of new drug target combination Read More

New data from the PACIFIC phase 3 trial published in the New England Journal of Medicine Read More

Dr. Robert Gillies honored for a lifetime of research in cancer imaging Read More

Read More

Behind the scenes, the Luca Lab studies the "molecular language" of cell-to-cell communication using cutting edge approaches in structural, cellular and synthetic biology. Read More

Less-frequently used combination associated with better response than standard of care Read More

Read More

Research suggests reducing inflammation through daily aspirin use can lower ovarian cancer risk and improve survival for those battling the disease Read More

Even though many people use the terms "antiperspirant" and "deodorant" interchangeably, antiperspirants are actually a subset of deodorants, and each works in a different way. Read More

Dr. Kosj Yamoah, a physician-scientist, tracks his roots of studying prostate cancer disparities through his native Ghana. Read More

Patients with certain fast-progressing and deadly types of acute myeloid leukemia (AML) saw the first new drug for their disease in more than 40 years approved by the FDA. Read More

The fourth one on the list of Moffitt research developments for 2017 involves rethinking drug resistance with a strategy called adaptive therapy that links the frequency, dosage and type of chemo to the tumor’s response. Read More

The third item on the list of Moffitt research developments for 2017 involves new targets for existing cancer-fighting drugs. Read More

The second one on the list of Moffitt research developments involves a grant to study how immunotherapy can change the way the cancer center is treating lung cancer. Read More

The first one on the list of Moffitt's top research developments for 2017 is the FDA approval of CAR T therapy for certain aggressive types of adult lymphoma. Read More

Lung cancer is by far the leading cause of cancer death among both men and women. More than 220,000 Americans are diagnosed with lung cancer every year. Read More

What if a drug commonly used to protect bones from osteoporosis could be altered to keep out breast cancer cells? That’s the goal one Moffitt researcher is pursuing through the creation of "Smart Molecules." Read More

More than 30,000 pounds of medical and hurricane supplies, generators, food and water are on a chartered Boeing 737 headed for Puerto Rico, which was devastated by Hurricane Maria. Read More

Dr. Daniel Abate-Daga's research is focused on the development of T cell-based immunotherapies for the treatment of cancer. Read More

Dr. Enderling is an assistant member in the Integrated Mathematical Oncology Department. Find out what his team accomplished at Miles for Moffitt this year. Read More

Dr. Doug Cress is an associate member of the Molecular Oncology Department. Learn more about his role in Molecular Oncology and the Spark Program. Read More

From caregivers to survivors and patients - more than 5,600 participants shared one common goal at Miles for Moffitt: raising funds for cancer research to save lives and ultimately defeat cancer. Read More

"We have all had loved ones who've been touched by cancer. I remember being struck by the huge quality of life burden that cancer patients and survivors face," says Dr. Gonzalez. Read More

Dr. Locke, the principal investigator for a new experimental immunotherapy called CAR T-cell therapy, talks about the breakthroughs with this type of treatment. Read More

How does math coincide with cancer treatment? The answer lies within the Integrated Mathematical Oncology Department at Moffitt Cancer Center. Read More

The health care needs of LGBTQ patients who are at risk or fighting cancer are a priority for continued research, Moffitt Cancer Center’s Gwendolyn Quinn, PhD, and Matthew Schabath, PhD, told ResearchAmerica.org prior to World Cancer Day on Feb. 4. Read More

At Moffitt Cancer Center we look at every patient’s cancer as unique. Our clinical expertise and transformational research keeps us at the forefront of personalizing cancer care. Read More

After 12 years, a significant study at Moffitt has come to an end. Read More

Moffitt Cancer Center hosted a Cancer Moonshot Summit bringing together physicians, scientists, patients, and advocates to discuss viable ways to accelerate cancer research and improve treatment. Read More

May is National Cancer Research Month, which serves as an important reminder to everyone that the key to future progress in the fight against cancer lies in the critical work that still needs to be done. Read More

Moffitt Cancer Center and the American Association for Cancer Research (AACR) hosted the Cancer Research Policy Forum in the Ted Couch Auditorium on Monday, March 7. Read More

Moffitt Eager to Play Role in Biden's 'Moon Shot' to Cure Cancer Read More